IMDX:NASDAQ, Insight Molecular Diagnostics Inc.

Why IMDX stock rose on November 20

Insight Molecular Diagnostics Inc. rose 18.7% on Friday, November 20, 2026, on 1,199,606 shares, 4.9 times its average daily volume. Headlines around the move:

IMDX stock overview

Insight Molecular Diagnostics Inc. (IMDX:NASDAQ) closed at $1.97 on November 20, 2026, up 18.67% on the day. The stock trades 73.8% below its 52-week high of $7.51 and 31.3% above its 52-week low of $1.50. Over the past year, it lost 67.8%. Insight Molecular Diagnostics Inc. is part of the Health Care sector.

Key figures

Price
$1.97
Day change
+18.67%
Volume
1,199,606
Average volume
243,745
Market cap
80M+
52-week range
$1.50 – $7.51
50-day average
$3.10
200-day average
$4.43

Price action over the past year

In 252 trading sessions since November 20, 2025, IMDX closed higher on 117 days (46%). Its best day was March 31, 2026 (+28.63%) and its worst was March 30, 2026 (-28.37%). The stock moved 10% or more in a single session 25 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

IMDX news

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc., or iMDx (formerly Oncocyte Corporation), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

Similar stocks

Find more stocks like IMDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.